• Pharma
  • June 6, 2025
  • 530 views
Wockhardt’s novel antibiotic Zaynich eyes $9 billion global market

Mumbai-based pharma major Wockhardt, which is all set to launch its new class of antibiotic Zaynich targeted at treating complicated gram-negative infections in India this year, estimates that the drug…

This multibagger pharma stock jumped 9% today; stock up 10x in 21 months

Shares of Wockhardt Ltd surged more than 9 per cent during the trading session on Friday to hit its new 52-week high after the national drug regulator approved a medicine…

  • Pharma
  • May 14, 2019
  • 210 views
Sun Pharma Dropped In Market After Us Lawsuit

Share prices of some leading domestic pharmaceutical companies, led by Sun Pharmaceutical Industries, fell 4-9 per cent on Monday, after being named in a price-fixing lawsuit in the US. The…

  • Health
  • August 1, 2018
  • 249 views
343 FDCs should continue banned as they expose Patients To health risks

An expert panel team appointed by the government has recommended the continuation of the ban on 343 fixed-dose combination (FDC) drugs. The expert sub-committee of the Drugs Technical Advisory Board…

  • Pharma
  • March 17, 2018
  • 258 views
Wockhardt, two others under lens for selling drugs without approval

New Delhi: Major drug makers, including Wockhardt Ltd, are under the scanner of the pharma regulator for allegedly launching combination drugs to treat diabetes and fungal infection without mandatory prior…